Observed Signal · Sep 23, 2026 · Funding · Source: techcrunch · Impact: 1/5 · Sentiment: Positive
Enveda raises $311M for AI drug discovery
Enveda, an AI-driven biotech startup focused on discovering drugs from natural sources, has raised $311 million in a Series E funding round at a $2 billion valuation. The round was led by Catalio Capital Management, with participation from Iconiq and others, doubling the company's valuation from 12 months ago. Enveda, founded in 2019 by Viswa Colluru, uses AI to accelerate the discovery of drugs from plants and microbes. The startup is currently advancing several drug candidates into clinical trials, including treatments for severe skin conditions and a drug designed to maintain weight loss after discontinuation of GLP-1s. This funding will support further clinical development.
Not relevant to AdTech/MarTech/Advertising/AI industry.
Track Real-Time Funding Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Enveda raised $311 million in Series E funding at a $2 billion valuation.
- Catalio Capital Management led the round, with participation from Iconiq and others.
- The new valuation doubles Enveda's valuation from 12 months ago.
- Enveda uses AI to discover drugs from natural sources like plants and microbes.
- The company is testing drugs for skin conditions and weight loss maintenance post-GLP-1.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Veeda raises $90M seed for multi-modal world models
A new AI startup called Veeda, founded by three former Nvidia employees including noted AI researcher Sanja Fidler, announced a $90 million seed funding round led by Khosla Ventures and Radical Ventures. Veeda plans to build multi-modal world models aimed at embodied intelligence and robotics. The story was first reported by The Logic; the article situates this round amid growing investor interest in world-model approaches and mentions potential acquisitions and activity from larger AI companies such as Anthropic.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Vivodyne builds robotic labs to improve AI drug discovery
Vivodyne, a biotech startup spun out of the University of Pennsylvania, says the AI drug‑discovery field lacks the causal human biological data needed to train useful models and has built HIVE — modular robotic labs that grow human tissues, autonomously dose and monitor them, and generate longitudinal experimental data. The company claims its tissues achieve high concordance with human trial outcomes (e.g., liver 94%, airway 96%, bone marrow 100% on tested chemotherapies), has raised just under $80 million across two rounds led by Khosla Ventures, and last week opened what it calls the world’s largest “human data center” near San Francisco to scale throughput and feed AI research. Vivodyne positions its dataset as a way to enable causal, reinforcement‑learning style models for more predictive human biology and combination‑therapy design.
Track Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.